Inspira Technologies Oxy B.H.N. Ltd. filings document foreign-private-issuer current reports, shareholder meeting materials and registration statement incorporation for its technology business. Form 6-K reports furnish press releases on AME system orders, commercial deployments, the QTREX platform, cryogenic interconnect development and shareholder communications, while proxy materials cover voting matters such as amendments to the company's articles of association.
Other filings describe governance and officer appointments, ordinary-share voting procedures, Form F-3 and Form S-8 registration statement references, and capital-structure context tied to the company's Nasdaq-listed securities and medical technology operations.
Inspira Technologies (IINN) furnished a Form 6-K announcing a press release titled “Inspira and Bites Form Strategic Alliance to Embed AI as a Core Standard Across Inspira’s Global Ecosystem.” The filing notes that the first four paragraphs and the “Forward-Looking Statements” section of the release are incorporated by reference into the company’s existing registration statements on Form F-3 and Form S-8, effective upon submission.
Inspira Technologies Oxy B.H.N. Ltd. (IINN) filed a Form 6-K announcing leadership additions. On October 21, 2025, the company furnished a press release titled “Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm.”
The first three paragraphs and the “Forward-Looking Statements” section of the release are incorporated by reference into Inspira’s Registration Statements on Forms F-3 and S-8, effective from the submission date, to the extent not superseded by later filings.
Inspira Technologies Oxy B.H.N. Ltd. (IINN) filed a Form 6-K announcing leadership additions. On October 21, 2025, the company furnished a press release titled “Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm.”
The first three paragraphs and the “Forward-Looking Statements” section of the release are incorporated by reference into Inspira’s Registration Statements on Forms F-3 and S-8, effective from the submission date, to the extent not superseded by later filings.
Inspira Technologies Oxy B.H.N. Ltd. filed a Form 6-K that packages its first half 2025 financial communication. The report furnishes a press release titled “Inspira Technologies Reports First Half 2025 Financial Results and Issues Business Update,” unaudited interim condensed consolidated financial statements as of June 30, 2025, and management’s discussion and analysis for the six months ended June 30, 2025.
These materials are also incorporated by reference into the company’s existing Form F-3 and Form S-8 registration statements, meaning the mid‑2025 financial information and business update become part of the disclosure record supporting those securities offerings.
Inspira Technologies Oxy B.H.N. Ltd. submitted a Form 6-K that incorporates by reference previously filed registration statements and furnishes a press release dated September 18, 2025. The press release announces that Inspira will unveil its HYLA™ real-time blood sensor at the U.S. ELSO conference and states the device has 97.35% accuracy confirmed. The filing is signed by Chief Executive Officer Dagi Ben-Noon. The document provides an event announcement and a specific accuracy figure for the product but does not include financial results, commercialization details, regulatory approvals, or timelines.
IINN is amending its at-the-market offering program with A.G.P./Alliance Global Partners to increase the maximum aggregate offering price of its ordinary shares that may be sold under the existing sales agreement from $7,117,720 to $9,985,579.
The company has already sold ordinary shares for an aggregate of approximately $4,701,062 under the sales agreement. A.G.P. acts as sales agent on a best efforts basis, earning a 3.0% commission on the gross sales price per share, and is deemed an underwriter for these transactions. The amendment confirms that the company’s capacity to sell securities under its Form F-3 pursuant to General Instruction I.B.5 is $9,985,579, with the ordinary shares listed on the Nasdaq Capital Market under the symbol IINN.
Inspira Technologies Oxy B.H.N. Ltd. filed a report noting it has increased the maximum aggregate offering price of its ordinary shares that may be issued under its existing Sales Agreement with A.G.P./Alliance Global Partners from $7,117,720 to $9,985,579. This agreement allows the company to sell ordinary shares from time to time, and the change expands the total dollar amount of shares that can be issued through this program.
The company also filed a legal opinion from Sullivan & Worcester Tel-Aviv (Har-Even & Co.) confirming the legality of issuing and selling these ordinary shares under the Sales Agreement. This report is incorporated by reference into multiple existing registration statements on Form F-3 and Form S-8, meaning those registration statements now include this updated at-the-market capacity.